Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

BIOCRYST PH Form 4 May 17, 2007	ARMACEUT	FICALS II	NC								
FORM 4	1								PPROVAL		
	STATES		RITIES A			COMMISSION	N OMB Number:	3235-0287			
Check this be if no longer subject to Section 16.	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Estimated	Expires: January 31, 2005 Estimated average burden hours per				
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1 Section 17(a) of the Public Utility Holding Company Act of 1935 or S 30(h) of the Investment Company Act of 1940							of 1935 or Section	response	•		
(Print or Type Resp	onses)										
1. Name and Address of Reporting Person <u>*</u> STEER RANDOLPH C			2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICAL INC [BCRX]			5. Relationship of Reporting Person(s) to IssuerLS (Check all applicable)					
(Last) 2190 PARKWA	. , , ,	Middle) RIVE		of Earliest T Day/Year) 2007	ransaction		X_ Director Officer (giv below)		% Owner her (specify		
	(Street)		4. If Amendment, Date Filed(Month/Day/Year)			Applicable Line)			oint/Group Filing(Check One Reporting Person		
BIRMINGHAM	M, AL 35244-						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	ransaction Date onth/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Report of	on a separate line	e for each el	ass of sec	Code V		(D) Price	or indirectly				
Actinities, Report	n a separate mit			unites bene.	Perso inforn requir	ns who res nation cont red to respo	spond to the colle ained in this form and unless the fo	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

number.

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Y	Year) (Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (1)	\$ 7.98	05/16/2007	А	15,000	06/16/2007	05/16/2017	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships					
r o o o o o o o o o o o o o o o o o o o	Director	10% Owner	Officer	Other		
STEER RANDOLPH C 2190 PARKWAY LAKE DRIVE BIRMINGHAM, AL 35244-	X					
Signatures						
Michael Richardson	05/17/200	07				

Date

by POA

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Automatic non-employee director grant

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.